HELRIK AND LOUW COMPANY LTD

Their core work

Helrik and Louw Company Ltd is a London-based private SME operating at the intersection of health, wellness, and applied life sciences. Their H2020 participation — both through MSCA-RISE staff exchange programs — suggests they serve as an industry host and knowledge partner for academic research, rather than a pure technology developer. Their project portfolio spans two related but distinct domains: the therapeutic effects of natural micro-environments on aging and well-being (including health tourism), and personalised post-surgical cancer care and immunotherapy outcomes. In MSCA-RISE arrangements, private companies typically provide industry context, patient/client populations, or commercial validation for academic partners, placing Helrik and Louw in a bridge role between research institutions and real-world healthcare or wellness applications.

What they specialise in

How they've shifted over time

In their earliest project (CHARMED, 2017), the focus was firmly on preventive and environmental health — green spaces, micro-environments, aging, and health tourism, all pointing toward wellness, lifestyle, and non-clinical interventions. By their second project (CANCER, 2018), the emphasis had shifted toward clinical outcomes: immunotherapy, less invasive surgical approaches, and postoperative quality of life. This represents a meaningful move along the care pathway — from upstream wellness and prevention toward downstream clinical treatment and recovery. The trajectory suggests the organisation is deepening its engagement with biomedical research, moving beyond lifestyle health into oncology-adjacent applications.

The organisation appears to be moving from preventive wellness toward clinical healthcare research, making them a plausible partner for projects combining patient wellbeing with medical treatment — particularly in oncology or post-acute care settings.

How they like to work

Helrik and Louw has participated exclusively as a consortium partner and has never led a project, which is typical for industry SMEs in MSCA-RISE arrangements where academic institutions hold the coordinating role. Despite only two projects, they have engaged with 29 unique partners across 7 countries, indicating participation in large, multi-institutional consortia rather than small focused teams. This breadth suggests they are valued as an industry node that adds commercial or applied context to academic-driven research, rather than a narrow technical specialist.

With 29 unique consortium partners across 7 countries from just two projects, Helrik and Louw has unusually broad network exposure for their project volume, reflecting the large multi-partner structures common in MSCA-RISE consortia. Their 7-country reach suggests a European network, though no single geographic cluster is identifiable from the available data.

What sets them apart

Helrik and Louw occupies a rare niche as a UK private SME that has engaged in both environmental wellness research and clinical oncology research through EU-funded staff exchange programmes — a combination that few small companies can claim. For consortium builders, their value lies in providing an industry anchor in projects that need to demonstrate real-world applicability in health, tourism, or patient care. Post-Brexit, their UK-based status may add specific value for consortia seeking to include non-EU industry partners within MSCA or Horizon Europe association arrangements.

Highlights from their portfolio

• CHARMED
  The only project for which EC funding is recorded (EUR 108,000), and the most thematically distinctive — combining green micro-environment science with health tourism and aging, a commercially relevant niche with growing market interest.
• CANCER
  A long-running project (2018-2023) on personalised postoperative immunotherapy, demonstrating this SME's connection to cutting-edge oncology research despite having no recorded EC funding allocation, suggesting a third-party or in-kind contribution role.